UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs

Nature (London), 2013-08, Vol.500 (7464), p.598-602

2013

Volltextzugriff (PDF)

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

Cancer research (Chicago, Ill.), 2015-04, Vol.75 (7), p.1413-1422

2015

Volltextzugriff (PDF)

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Molecular cancer therapeutics, 2020-08, Vol.19 (8), p.1708-1718

2020

Volltextzugriff (PDF)

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

Nature communications, 2018-11, Vol.9 (1), p.4700-16, Article 4700

2018

Volltextzugriff (PDF)

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Molecular cancer therapeutics, 2019-10, Vol.18 (10), p.1875-1886

2019

Volltextzugriff (PDF)

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC

Oncogene, 2019-01, Vol.38 (1), p.17-32

2019

Volltextzugriff (PDF)

Development of a stress response therapy targeting aggressive prostate cancer

Science translational medicine, 2018-05, Vol.10 (439)

2018

Volltextzugriff (PDF)

KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis

Cell reports (Cambridge), 2016-09, Vol.16 (11), p.3016-3027

2016

Volltextzugriff (PDF)

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Molecular cancer therapeutics, 2018-10, Vol.17 (10), p.2197-2205

2018

Volltextzugriff (PDF)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models

Pharmacological research, 2023-03, Vol.189, p.106692-106692, Article 106692

2023

Volltextzugriff (PDF)

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1521-1530

2017

Volltextzugriff (PDF)

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Molecular cancer therapeutics, 2022-10, Vol.21 (10), p.1594-1607

2022

Volltextzugriff (PDF)

Targeting molecular resistance in castration-resistant prostate cancer

BMC medicine, 2015-09, Vol.13 (1), p.206-206, Article 206

2015

Volltextzugriff (PDF)

Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (25), p.9235-9240

2014

Volltextzugriff (PDF)

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer

Nature communications, 2024-08, Vol.15 (1), p.6626-20, Article 6626

2024

Volltextzugriff (PDF)

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

Cancer research (Chicago, Ill.), 2015-12, Vol.75 (24), p.5309-5317

2015

Volltextzugriff (PDF)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e006581

2023

Volltextzugriff (PDF)

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Biomedicines, 2022-07, Vol.10 (8), p.1778

2022

Volltextzugriff (PDF)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

Translational andrology and urology, 2015-06, Vol.4 (3), p.365-380

2015

Volltextzugriff (PDF)

Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells

Clinical cancer research, 2009-08, Vol.15 (15), p.4815-4822

2009

Volltextzugriff (PDF)

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy

Cancers, 2017-01, Vol.9 (1), p.9

2017

Volltextzugriff (PDF)

Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (1), p.151-160

2009

Volltextzugriff (PDF)

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration

International journal of cancer, 2012-06, Vol.130 (11), p.2693-2702

2012

Volltextzugriff (PDF)

Autophagy as a modulator and target in prostate cancer

Nature reviews. Urology, 2014-09, Vol.11 (9), p.508-516

2014

Volltextzugriff (PDF)

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1629-1637

2010

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(113)
Tagungsberichte
(1)

Sprache

Englisch
(114)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(43)
Humans
(40)
Male
(37)
Animals
(26)
Prostate Cancer
(24)
Cell Line, Tumor
(21)
Oncology
(20)
Mice
(19)
Androgens
(15)
Receptors, Androgen - Metabolism
(15)
Prostatic Neoplasms - Drug Therapy
(14)
Prostatic Neoplasms - Metabolism
(13)
Tumors
(13)
Biochemistry & Molecular Biology
(12)
Science & Technology - Other Topics
(11)
Urology
(11)
Apoptosis
(10)
Cell Biology
(10)
Prostatic Neoplasms - Genetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC

Development of a stress response therapy targeting aggressive prostate cancer

KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Targeting molecular resistance in castration-resistant prostate cancer

Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy

Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration

Autophagy as a modulator and target in prostate cancer

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

Suchergebnisse filtern